Skip to main content
SpringerLink
Log in

Cytogenetics of Malignant Mesothelioma

  • Chapter
Malignant Mesothelioma

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Antman KH, Pass HI, Schiff PB. Management of mesothelioma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins, 2001:1943–1969.

    Google Scholar 

  2. Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology 1997;30:403–418.

    Article  PubMed  CAS  Google Scholar 

  3. Craighead JE, Mossman BT. The pathogenesis of asbestos-associated diseases. N Engl J Med 1982;306:1446–1455.

    Article  PubMed  CAS  Google Scholar 

  4. Butel JS, Lednicky JA. Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst 1999;91:119–134.

    Article  PubMed  CAS  Google Scholar 

  5. Carbone M, Fisher S, Powers A, Pass HI, Rizzo P. New molecular and epidemiological issues in mesothelioma: role of SV40. J Cell Physiol 1999;180:167–172.

    Article  PubMed  CAS  Google Scholar 

  6. Carbone M, Rizzo P, Pass HI. Simian virus 40, poliovaccines and human tumors: a review of recent developments (meeting review). Oncogene 1997;15:1877–1888.

    Article  PubMed  CAS  Google Scholar 

  7. Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999;180:150–157.

    Article  PubMed  CAS  Google Scholar 

  8. Testa JR, Pass HI, Carbone M. Molecular biology of mesothelioma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins, 2001:1937–1943.

    Google Scholar 

  9. Testa JR, Jhanwar SC. Molecular genetics of malignant mesothelioma. In: Light RW, Lee G, eds. Pleural Disease: An International Textbook. London: Arnold Publishers, (in press.)

    Google Scholar 

  10. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993;53:4349–4355.

    PubMed  CAS  Google Scholar 

  11. Balsara BR, Bell DW, Sonoda G, et al. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1–15 in human malignant mesothelioma. Cancer Res 1999;59:450–454.

    PubMed  CAS  Google Scholar 

  12. Bjorkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 1997;75:523–527.

    PubMed  CAS  Google Scholar 

  13. Bjorkqvist AM, Tammilehto L, Nordling S, et al. Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer 1998;77:260–269.

    PubMed  CAS  Google Scholar 

  14. Hirvonen A, Mattson K, Karjalainen A, et al. SV40-like DNA sequences not detectable in Finnish mesothelioma patients not exposed to SV40 contaminated poliovaccines. Mol Carc 1999;26:93–99.

    Article  CAS  Google Scholar 

  15. Krismann M, Muller KM, Jaworska M, Johnen G. Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J Pathol 2002;197:363–371.

    Article  PubMed  CAS  Google Scholar 

  16. Kivipensas P, Bjorkqvist AM, Karhu R, et al. Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 1996;89:7–13.

    Article  PubMed  CAS  Google Scholar 

  17. Seemayer TA, Cavenee WK. Molecular mechanisms of oncogenesis. Lab Invest 1989;60:585–599.

    PubMed  CAS  Google Scholar 

  18. Weinberg RA. Tumor suppressor genes. Science 1991;254:1138–1146.

    PubMed  CAS  Google Scholar 

  19. Knudson AG Jr. Hereditary cancers disclose a class of cancer genes. Cancer 1989;63:1888–1891.

    Article  PubMed  Google Scholar 

  20. Lee W-C, Balsara B, Liu Z, Jhanwar SC, Testa JR. Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res 1996;56:4297–4301.

    PubMed  CAS  Google Scholar 

  21. Apostolou S, De Rienzo A, Murthy SS, Jhanwar SC, Testa JR. Absence of BCL10 mutations in human malignant mesothelioma. Cell 1999;97:684–686.

    Article  PubMed  CAS  Google Scholar 

  22. Willis TG, Jadayel DM, Du M-Q, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999;96:35–45.

    Article  PubMed  CAS  Google Scholar 

  23. Lu YY, Jhanwar SC, Cheng JQ, Testa JR. Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes Cancer 1994;9:76–80.

    PubMed  CAS  Google Scholar 

  24. Zeiger MA, Gnarra JR, Zbar B, Linehan WM, Pass HI. Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes Cancer 1994;11:15–20.

    PubMed  CAS  Google Scholar 

  25. Shigemitsu K, Sekido Y, Usami N, et al. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 2001;20:4249–4257.

    Article  PubMed  CAS  Google Scholar 

  26. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315–319.

    Article  PubMed  CAS  Google Scholar 

  27. Toyooka S, Carbone M, Toyooka K, et al. Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene 2002;21:4340–4344.

    Article  PubMed  CAS  Google Scholar 

  28. Shivapurkar N, Virmani AK, Wistuba II, et al. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res 1999;5:17–23.

    PubMed  CAS  Google Scholar 

  29. Bell DW, Jhanwar SC, Testa JR. Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 1997;57:4057–4062.

    PubMed  CAS  Google Scholar 

  30. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436–440.

    PubMed  CAS  Google Scholar 

  31. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21–p22 in malignant mesothelioma. Cancer Res 1994;54:5547–5551.

    PubMed  CAS  Google Scholar 

  32. Kratzke RA, Otterson GA, Lincoln CE, et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995;87:1870–1875.

    PubMed  CAS  Google Scholar 

  33. Frizelle SP, Grim J, Zhou J, et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998;16:3087–3095.

    Article  PubMed  CAS  Google Scholar 

  34. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 1998;395:125–126.

    Article  PubMed  CAS  Google Scholar 

  35. Yang CT, You L, Yeh CC, et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000;92:636–641.

    Article  PubMed  CAS  Google Scholar 

  36. De Rienzo A, Jhanwar SC, Testa JR. Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. Genes Chromosomes Cancer 2000;28:337–341.

    Article  PubMed  Google Scholar 

  37. Van Der Meeren A, Seddon MB, Kispert J. Lack of expression of the retinoblastoma gene is not frequently involved in the genesis of human mesothelioma. Eur Respir Rev 1993;3:177–179.

    Google Scholar 

  38. De Rienzo A, Balsara BR, Apostolou S, Jhanwar SC, Testa JR. Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma. Oncogene 2001;20:6245–6249.

    Article  PubMed  CAS  Google Scholar 

  39. Cote RJ, Jhanwar SC, Novick S, Pellicer A. Genetic alterations of the p53 gene are a feature of malignant mesothelioma. Cancer Res 1991;51:5410–5416.

    PubMed  CAS  Google Scholar 

  40. Metcalf RA, Welsh JA, Bennett WP, et al. p53 and Kirstein-ras mutations in human mesothelioma cell lines. Cancer Res 1992;52:2610–2615.

    PubMed  CAS  Google Scholar 

  41. Bianchi AB, Hara T, Ramesh V, et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 1994;6:185–192.

    Article  PubMed  CAS  Google Scholar 

  42. Kissil JL, Johnson KC, Eckman MS, Jacks T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 2002;277:10394–10399.

    Article  PubMed  CAS  Google Scholar 

  43. Xiao GH, Beeser A, Chernoff J, Testa JR. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 2002;277:883–886.

    Article  PubMed  CAS  Google Scholar 

  44. Sells MA, Boyd JT, Chernoff J. p21-activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts. J Cell Biol 1999;145:837–849.

    Article  PubMed  CAS  Google Scholar 

  45. Sekido Y, Pass HI, Bader S, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227–1231.

    PubMed  CAS  Google Scholar 

  46. Cheng JQ, Lee W-C, Klein MA, Cheng GZ, Jhanwar SC, Testa JR. Frequent alterations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 1999;24:238–242.

    Article  PubMed  CAS  Google Scholar 

  47. Snijders AM, Nowak N, Segraves R, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001;29:263–264.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Human Genetics Program, Fox Chase Cancer Center, Philadelphia, PA, USA

    Sinoula Apostolou PhD & Binaifer R. Balsara PhD

  2. Human Genetics Program, Population Science, Department of Population Science, Fox Chase Cancer Center, Philadelphia, PA, USA

    Joseph R. Testa PhD (Senior Member)

Authors
  1. Sinoula Apostolou PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Binaifer R. Balsara PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph R. Testa PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Thoracic Oncology, Barbara Ann Karmanos Cancer Institute, Harper University Hospital, USA

    Harvey I. Pass MD (Chief and Professor of Surgery and Oncology) (Chief and Professor of Surgery and Oncology)

  2. Wayne State University School of Medicine, Detroit, MI, 48201, USA

    Harvey I. Pass MD (Chief and Professor of Surgery and Oncology) (Chief and Professor of Surgery and Oncology)

  3. Nevada Cancer Institute, USA

    Nicholas J. Vogelzang MD (Director and Clinical Professor) (Director and Clinical Professor)

  4. Department of Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV, 81935, USA

    Nicholas J. Vogelzang MD (Director and Clinical Professor) (Director and Clinical Professor)

  5. Thoracic Oncology, Cardinal Bernardin Cancer Center, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, 60153, USA

    Michele Carbone MD, PhD (Professor of Pathology, Director) (Professor of Pathology, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Apostolou, S., Balsara, B.R., Testa, J.R. (2005). Cytogenetics of Malignant Mesothelioma. In: Pass, H.I., Vogelzang, N.J., Carbone, M. (eds) Malignant Mesothelioma. Springer, New York, NY. https://doi.org/10.1007/0-387-28274-2_6

Download citation

  • DOI: https://doi.org/10.1007/0-387-28274-2_6

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-22949-2

  • Online ISBN: 978-0-387-28274-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation